National strategy for combating and eliminating tuberculosis

(a)

In general

Section 317E of the Public Health Service Act (42 U.S.C. 247b–6) is amended— (1)in subsection (a)— (A)by striking The Secretary and inserting the following:

(1)

Grants

The Secretary

; and

(B)by adding at the end the following:

(2)

Priority

In making grants under this subsection, the Secretary may give priority to awarding grants to State health departments proposing to focus on the prevention, control, and elimination of tuberculosis in high-risk populations, including foreign-born, homeless, incarcerated, HIV-tuberculosis coinfected, and medically underserved populations.

;

(2)in subsection (b)— (A)in paragraph (3)— (i)in subparagraph (C), by redesignating clauses (i) and (ii) as subclauses (I) and (II), respectively, and adjusting the margins accordingly; and (ii)by redesignating subparagraphs (A) through (F) as clauses (i) through (vi), respectively, and adjusting the margins accordingly; (B)by redesignating paragraphs (1) through (8) as subparagraphs (A) through (H), respectively, and adjusting the margins accordingly; (C)in the matter preceding subparagraph (A), as so redesignated, by striking With respect to and inserting the following:

(1)

In general

With respect to

;

(D)by striking subparagraph (B), as so redesignated, and inserting the following:

(B)Research, investigations, experiments, demonstrations, and studies in the health sciences that are related to— (i)the development of new therapeutics, including vaccines and antimicrobial drugs, to prevent and treat tuberculosis; (ii)novel therapeutics for special populations, including pediatric populations, immunosuppressed individuals, and pregnant women; (iii)the development or testing of medical diagnostics to detect tuberculosis; (iv)public health interventions to address the epidemiology, mechanisms, and pathogenesis of tuberculosis, such as directly observed therapy and non-pharmaceutical intervention; (v)methods to enhance detection and response to outbreaks of tuberculosis, including multidrug resistant tuberculosis; and (vi)other relevant research areas.

;

(E)in subparagraph (C), as so redesignated— (i)by redesignating clause (vi), as so redesignated, as clause (vii); (ii)in clause (v), as so redesignated, by striking ; and and inserting ;; and (iii)by inserting after clause (v), as so redesignated, the following:

(vi)the intensification of efforts to prevent, detect, and treat latent tuberculosis; and

;

(F)in subparagraph (D), as so redesignated, by inserting before the period the following: , including public awareness campaigns and development of educational, risk, and media communications.; (G)in subparagraph (F), as so redesignated, by striking paragraphs (1) through (4) and inserting subparagraphs (A) through (D); and (H)by adding at the end the following:

(2)

Selection

In carrying out the activities described in paragraph (1), the Secretary— (A)is encouraged to give priority to programmatically relevant research so that new tools can be utilized in public health practice; and (B)may seek input from the Biomedical Advanced Research and Development Authority in identifying novel candidates to utilize in the efforts under this subsection to prevent, diagnose, and control tuberculosis.

;

(3)by redesignating subsections (c) through (h) as subsections (d) through (i), respectively; (4)by inserting after subsection (b) the following—

(c)

Grants for coordination of programs and services for prevention, diagnosis, and treatment

(1)

Grants

The Secretary, acting through the Administrator of the Health Resources and Services Administration, may award grants to State and local governments and Federally qualified health centers for coordinating the programs and services of such States, governments, and centers to ensure timely and appropriate prevention, risk-based screening, diagnosis, and treatment of latent and active tuberculosis. (2)

Definition

In this subsection, the term Federally qualified health center has the meaning given to such term in section 1861(aa) of the Social Security Act.

;

(5)in subsections (d), (e), and (f), as so redesignated, by striking (a) or (b) each place it appears and inserting (a), (b), or (c); (6)in subsection (g)(4), as so redesignated, by adding at the end the following:

(C)

Report to Congress

The Secretary is encouraged to make the reports under subparagraph (A), or other publications relevant to domestic tuberculosis surveillance, publicly available on the Internet website of the Centers for Disease Control and Prevention and disseminate such information to stakeholders.

;

(7)in subsection (h), as so redesignated— (A)in paragraph (1)— (i)by striking research into new tools under subsection (b)(2) and inserting the research, investigations, experiments, demonstrations, and studies in health science under subsection (b)(1)(B); and (ii)by inserting ensuring access to the products developed as a result of such research, investigations, experiments, demonstrations, and studies and after advice regarding; and (B)in paragraph (3)— (i)by redesignating subparagraphs (D) and (E) as subparagraphs (E) and (F), respectively; and (ii)by inserting after subparagraph (C) the following:

(D)members of the Biomedical Advanced Research and Development Authority;

; and

(8)in subsection (i)(1)(A), as so redesignated, by striking $200,000,000 and all that follows through the period and inserting $142,200,000 for fiscal year 2018, $195,700,000 for fiscal year 2019, $225,000,000 for fiscal year 2020, $236,250,000 for fiscal year 2021, $248,062,500 for fiscal year 2022, and $260,465,625 for fiscal year 2023.. (b)

NIH tuberculosis activities

Section 424C(b) of the Public Health Service Act (42 U.S.C. 285b–7c(b)) is amended by striking paragraph (1) and inserting the following:

(1)enhancing basic, clinical, and operational research on tuberculosis, including with respect to— (A)drug-resistant tuberculosis; (B)infection with tuberculosis and latency and progression of tuberculosis; and (C)pediatric tuberculosis;